

# OvaScience

## Preconception planning

The US AUGMENT study was initiated in late-2012, which infers the first live birth could occur in late-2013/early-2014. However, we believe that interim updates on the trial are unlikely before final data in H214. OvaScience is increasing its commercial activities around AUGMENT and is progressing ex-US trial plans. The latter represents upside to our rNPV of \$200m, which currently reflects the initial US opportunity for AUGMENT.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	0.0	(12.1)	(2.09)	0.00	N/A	N/A
12/13e	0.0	(18.8)	(1.09)	0.00	N/A	N/A
12/14e	1.0	(21.7)	(1.19)	0.00	N/A	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

## US AUGMENT study ongoing...

Lead programme, AUGMENT, which adds a woman's egg precursor cell (EggPC) mitochondria to her eggs to increase the success of *in vitro* fertilisation (IVF), is in an ongoing US study with headline results expected in H214. Given that the AUGMENT study started in late-2012, the first live birth is likely to occur in late-13/early-14. However, interim efficacy/safety updates are unlikely (unless material) before final readout. Separately, a recent [publication](#) by OvaScience's scientific co-founders lends further support to using EggPC mitochondria to rejuvenate eggs.

## ...coupled with increasing commercial activities

OvaScience has also initiated commercial activities for AUGMENT, which includes [presentations](#) at key fertility conferences (increasing awareness of the procedure among physicians), new hires with significant commercial experience (the CSO was former R&D head for Shire) and creation of an International Product Advisory Board (IPAB). We project an H214 launch and peak US sales of \$159m in the initial indication (women requiring donor eggs or aged >35 failing multiple IVF cycles).

## Progressing ex-US AUGMENT plans

We expect an ex-US AUGMENT trial to start in H114. The IPAB members (primarily fertility experts from the UK, Spain and Germany) points to Europe (c 530k IVF cycles annually) as the most likely region. Moreover, UK government backing for three-person IVF (donor mitochondrial transfer) suggests the UK fertility regulator (HFEA) could be receptive to AUGMENT (autologous mitochondrial transfer). Pending further clarity, our financial model currently excludes ex-US sales of AUGMENT.

## Valuation: rNPV of \$200m reflects US opportunity

Edison's rNPV of \$200m attributes \$167m to AUGMENT in the US, adds cash of \$45m and deducts general costs of \$12m. Positive AUGMENT trial results would see our rNPV rise to \$312m. The ex-US AUGMENT opportunity currently represents pure upside to our valuation, although it appears the market is already ascribing value to this. As the European market (annual IVF procedures) is c 4x larger than the US, this suggests significant upside potential to our rNPV.

AUGMENT progressing

Pharma & biotech

12 August 2013

**Price** US\$12.62  
**Market cap** US\$230m

Net cash (\$m) at end-FY13e \$45.2m  
 Shares in issue 18.2m  
 Free float 51%  
 Code OVSC  
 Primary exchange NASDAQ

## Share price performance



%	1m	3m	12m
Abs	(6.4)	11.8	N/A
Rel (local)	(8.5)	7.5	N/A
52-week high/low	US\$15.6	US\$7.5	

## Business description

OvaScience is a US-based life sciences company focused on developing and commercialising new treatments for female infertility. Product candidates (AUGMENT, OvaTure) are based on the discovery of germline stem cells (egg precursor cells) in human ovaries. Both products are designed to improve the *in vitro* fertilisation (IVF) procedure, although OvaTure does not require hormone injections.

## Next events

AUGMENT US study expansion	H213
AUGMENT ex-US study initiation	H114
OvaTure human preclinical POC data	H114
AUGMENT potential US/ex-US launches	H214

## Analysts

Dr Mike Aitkenhead	+44 (0)20 3077 5736
Robin Davison	+44 (0)20 3077 5737

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

## OvaScience datasheet

Exhibit 1: OvaScience's R&D pipeline		
Programme	AUGMENT	OvaTure
Description	Procedure involves isolating mitochondria from a woman's own egg precursor cells (EggPC) and injecting them into her egg along with a sperm cell during IVF.	Creation of mature, fertilisable eggs <i>in vitro</i> using a woman's own egg precursor cells.
Therapeutic aim	Increase the success rate of IVF – adding EggPC mitochondria could improve egg quality and therefore increase the likelihood that a fertilised egg will develop into a viable embryo. This could reduce the number of IVF cycles and the number of embryos transferred to achieve a live birth.	Allow women to undergo IVF with high-quality non-donor eggs. This could (1) restore fertility in women with poor quality eggs (ie post-chemotherapy) and reduce the need for donor eggs, and (2) eliminate need for hormonal hyperstimulation required in IVF.
Stage	Clinical study	Preclinical development
Study details	AUGMENT study in up to 40 women aged 38-42 who have failed two to five cycles of IVF. Open-label study at two US IVF clinics with no formal control arm. Primary objective: safety; secondary objectives: embryo quality, fertilisation, pregnancy, live birth rates. Results for AUGMENT-treated patients will be compared to success rates (historical and concurrent, patient matched) for patients receiving standard IVF at the two clinics.	Broad outline of preclinical development plan: (1) Optimise the culture conditions used <i>in vitro</i> to transform EggPC into mature, fertilisable eggs – identify the optimal composition and sequence of proteins/factors necessary for creating new eggs. (2) Further preclinical mouse studies to confirm earlier research that EggPC can be matured into eggs, be fertilised and generate healthy offspring. (3) Preclinical human POC study using human EggPC – attempt to mature human EggPC <i>ex vivo</i> into fertilisable eggs using the optimised culture conditions.
Timeline	AUGMENT study initiated in late-2012. US study expansion in H213, headline results in H214, potential US and selected ex-US commercial launches from Q414. Ex-US study planned for H114.	Preclinical development started in 2012 and is expected to complete in H114.
Patent protection	Five patent families. Patents granted (and pending), which expire in May 2025. Additional patent applications that would, if granted, expire April-June 2032.	Five patent families. Patents granted (and pending) to May 2025. Additional patent applications, which would expire April-June 2032.
Potential regulatory pathway	361 HCT/P: a lower-risk human cell and tissue product (HCT/P) pathway.	New Biologics Licence Application (BLA) process.

Source: Edison Investment Research

### Exhibit 2: Clinical studies of mitochondrial transfer

Procedure	Mitochondria source	Cell type	Number of mitochondria transferred	Number of cycles	Live births	Offspring delivered	Implied live-birth success rate	Clinical trial(s)
Cytoplasmic transfer	Donor	Egg	Unknown	30	12	16	40%	Cohen et al (1997,1998); Brenner et al (2000);Barritt et al (2000,2001)
Cytoplasmic transfer	Donor	Egg	Unknown	4	1	2	25%	Lazendorf (1999)
Cytoplasmic transfer	Donor	Egg	Unknown	9	4	5	44%	Huang et al (1999)
Mitochondrial transfer	Autologous	Granulosa (somatic cell)	3000 (average)	71	20	27	28%	Tzeng et al (2004)

Source: Edison Investment Research

### Exhibit 3: AUGMENT criteria for regulation under 361 HCT/P

Criteria for 361 HCT/P	Does AUGMENT meet criteria?
HCT/P is minimally manipulated.	AUGMENT is prepared using simple cell-handling techniques to identify and isolate EggPCs, and centrifugation of EggPCs to separate out mitochondria. These steps do not alter the biological characteristics of the mitochondria.
HCT/P is intended for homologous use only.	AUGMENT supplements a woman's pre-existing egg mitochondria with fresh mitochondria from her own EggPCs.
Manufacture of the HCT/P does not involve the combination of cells or tissues with another article.	AUGMENT does not involve combining the HCT/P with any drugs, devices or synthetic materials. Mitochondria are diluted in standard ICSI buffer only.
HCT/P does not have a systemic effect and is not dependent on the metabolic activity of living cells for its primary function, or the HCT/P has a systemic effect or is dependent on the metabolic activity of living cells for its primary function and (a) is for autologous use, (b) is for allogeneic use in a first- or second-degree blood relative, or (c) is for reproductive use.	AUGMENT is intended for reproductive use and is autologous.

Source: Edison Investment Research

## Update: Preconception planning

---

### US AUGMENT study ongoing

Lead programme, AUGMENT, which adds a woman's egg precursor cell (EggPC) mitochondria to her eggs to increase the success of *in vitro* fertilisation (IVF), is in an ongoing US study with headline results expected H214. The AUGMENT study is enrolling female patients at two IVF clinics – we provided a detailed discussion of the open-label, non-randomised 40-patient trial in our [initiation of coverage](#) report. The AUGMENT study started in late-2012, which suggests that the first women are likely to have undergone the procedure in Q113. Based on a standard nine-month gestation, this infers that the first live birth could occur around late-2013/early-2014. However, the company has stated that interim efficacy/safety updates are unlikely (unless material) before final trial readout in 2014. Separately, a recent and detailed journal [publication](#) by OvaScience's scientific co-founders lends further support to using EggPC mitochondria to rejuvenate eggs.

### Progressing ex-US AUGMENT plans

OvaScience has already announced its intention to start an ex-US AUGMENT trial in H114. Given the membership of the recently created IPAB members (primarily fertility experts from the UK, Spain and Germany), we see Europe (c 530k IVF cycles annually) as the most likely territory for initial ex-US development.

Interestingly, the UK government is pushing ahead with plans to allow three-person IVF (donor mitochondrial transfer) to treat inherited mitochondrial disorders. The procedure is designed to create a healthy embryo by replacing the defective (maternal) mitochondria with healthy (donated) mitochondria. The embryos are then used in standard IVF treatment. The result is a baby with genetic information from three people – the mother and father (nuclear DNA) and a donor (the mitochondrial DNA). UK government support for three-person IVF follows a consultation by the UK fertility regulator, the Human Fertilisation and Embryology Authority (HFEA) published in March 2013, which concluded that mitochondrial replacement is probably safe and that there is general public support. Draft regulations are expected to be ready by Q413 and debated in parliament in 2014.

With the UK government and HFEA backing donor mitochondrial transfer (albeit only for inherited mitochondrial disorders), it suggests the HFEA may also be receptive to autologous mitochondrial transfer (AUGMENT), which does not introduce third-party DNA into the embryo. The UK Human Fertilisation and Embryology Act (2008) currently prohibits IVF treatment using eggs in which the nuclear or mitochondrial DNA have been altered. While OvaScience interprets this legislation as not preventing the use of AUGMENT in the UK, the HFEA could take a different view and prevent IVF clinics from undertaking the procedure. However, in our view, further amendments of the Act to allow three-person IVF could reduce the clinical and commercial risks for AUGMENT in the UK market.

We also note that the US regulator (FDA) is convening a Cellular, Tissue and Gene Therapies Advisory Committee in Q413 ([October 22-23](#)) to discuss 'oocyte modification in assisted reproduction for the prevention of transmission of mitochondrial disease or treatment of infertility'. While the detailed background materials are not yet available, we assume this Adcom relates to the use of three-person IVF. In our view, the Adcom is relevant to OvaScience, as it may also provide an insight into the FDA's thinking on the use of autologous mitochondrial transfer in IVF.

## Sensitivities

OvaScience is subject to the risks normally associated with biotech company development, including the possibility of unfavourable outcomes in clinical trials and the success of competitors. Because of its lack of diversification, there is particularly high sensitivity to the outcome of the AUGMENT study – negative data could represent a significant setback. Regulatory risk represents another key sensitivity. The FDA may decide to regulate AUGMENT as a new drug/biologic and require further clinical studies. This could substantially increase development costs and timelines, and may require additional capital.

## Valuation

We value OvaScience at \$200m, or \$11.0 per share, based on a risk-adjusted NPV analysis. We forecast 10-year cash flows from AUGMENT in its initial indication (US women aged >35yrs failing multiple IVF cycles) and discount using a 12.5% WACC. We attribute \$167m (\$9.20/share) to AUGMENT, add cash of \$45m (\$2.50/share) and deduct general costs of \$13m (\$0.70/share), to arrive at our \$11.0 fair value. Depending on the outcome of the AUGMENT study (ie unwinding our 60% risk adjustment for positive safety and efficacy data), our valuation could rise by c 55% to \$312m, or \$17.20 per share. We currently assign no value to AUGMENT in ex-US markets or to OvaTure, so these represent pure upside.

**Exhibit 4: rNPV valuation model and key assumptions**

Product	Indication	rNPV (\$m)	rNPV/share (\$)	Probability of success	Launch	Peak sales (\$m)	Key assumptions
AUGMENT	IVF	166.8	9.2	60%	2014	159	US market only: women >35yrs failing >2 IVF cycles; peak 25% share of 24k eligible women; price \$15,000.
R&D expenses		(1.7)	(0.1)				Preclinical R&D expenses for OvaTure.
G&A expenses		(9.2)	(0.5)				General overhead costs not attributable to AUGMENT.
Capex		(0.8)	(0.1)				Laboratory supplies and equipment.
Net cash		45.2	2.5				Forecast net cash at year-end 2013.
<b>Total</b>		<b>200.3</b>	<b>11.0</b>				rNPV of \$11/share based on 18.2m basic shares; rNPV based on fully diluted shares (20.8m) is \$10/share.

Source: Edison Investment Research

## Financials

Our financial model remains unchanged, pending details on the planned ex-US trial for AUGMENT. OvaScience ended 2012 with net cash of \$31.4m. Factoring in the \$35m (\$33m net) financing in March 2013 and expected cash utilisation, we project net cash of \$45.2m at year-end 2013. We estimate that the company's cash runway extends into late-2015/early-2016.

**Exhibit 5: Financial summary**

	\$'000s	2012	2013e	2014e
Year ending 31 Dec				
<b>PROFIT &amp; LOSS (\$'000)</b>				
Revenue		0	0	1,004
EBITDA		(12,054)	(18,846)	(21,740)
Operating profit (before GW and except)		(12,147)	(18,946)	(21,840)
Intangible amortisation		0	0	0
Exceptionals/special items		0	0	0
Share-based payment		(1,382)	(1,000)	(1,000)
Operating profit		(13,529)	(19,946)	(22,840)
Net interest		19	192	171
Profit before tax (norm)		(12,128)	(18,754)	(21,669)
Tax		0	0	0
Profit after tax (norm.)		(12,128)	(18,754)	(21,669)
Average number of shares outstanding (m)		5.8	17.2	18.2
EPS - normalised (c)		(209)	(109)	(119)
Dividend per share (c)		0.0	0.0	0.0
EBITDA margin (%)		N/A	N/A	N/A
Operating margin (before GW and except) (%)		N/A	N/A	N/A
<b>BALANCE SHEET</b>				
Fixed assets		849	1,249	1,649
Intangible assets		0	0	0
Tangible assets		849	1,249	1,649
Investment in associates/other non-core assets		0	0	0
Trade investment & others		0	0	0
Associated with assets held for sale		0	0	0
Current assets		31,965	45,237	23,167
Stocks		0	0	0
Debtors		0	0	0
Cash		31,391	45,237	23,167
Other		574	0	0
Current liabilities		(2,086)	(2,086)	(2,086)
Creditors		(2,086)	(2,086)	(2,086)
Other creditors		0	0	0
Short-term borrowings		0	0	0
Provisions and other current liabilities		0	0	0
Associated with assets held for sale		0	0	0
Long-term liabilities		(7)	0	0
Long-term borrowings		0	0	0
Deferred taxation		0	0	0
Other long-term liabilities		(7)	0	0
Net assets		30,721	44,400	22,730
<b>CASH FLOW</b>				
Operating cash flow		(10,643)	(18,846)	(21,740)
Net interest		19	192	171
Tax		0	0	0
Capex		(849)	(500)	(500)
Purchase of intangibles		0	0	0
Acquisitions/disposals		0	0	0
Financing		39,031	33,000	0
Dividends		0	0	0
Other		(708)	0	0
Net cash flow		26,850	13,846	(22,069)
Opening net debt/(cash)		(4,541)	(31,391)	(45,237)
HP finance leases initiated		0	0	0
Other		0	0	0
Closing net debt/(cash)		(31,391)	(45,237)	(23,167)

Source: Edison investment Research, OvaScience accounts

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is not regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244] [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by OvaScience and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is not registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE [2013]. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Berlin +49 (0)30 2088 9525  
Friedrichstrasse 95  
10117 Berlin  
Germany

London +44 (0)20 3077 5700  
280 High Holborn  
London, WC1V 7EE  
United Kingdom

New York +1 646 653 7026  
245 Park Avenue, 39th Floor  
10167, New York  
US

Sydney +61 (0)2 9258 1162  
Level 33, Australia Square  
264 George St, Sydney  
NSW 2000, Australia

Wellington +64 (0)4 8948 555  
Level 15, 171 Featherston St  
Wellington 6011  
New Zealand